Published in Pharmacogenet Genomics on December 01, 2012
Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics | NCT01386970
Individualization of antiretroviral therapy - Pharmacogenomic aspect. Indian J Med Res (2015) 0.75
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med (2002) 4.77
Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med (1990) 3.52
3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother (1987) 2.60
Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos (2010) 1.74
Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS (2003) 1.69
A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen (2007) 1.49
In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis (2005) 1.43
Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos (2003) 1.38
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr (2006) 1.35
3'-azido-3'-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J Biol Chem (1987) 1.32
Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther (2002) 1.31
The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther (2008) 1.23
Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol Pharmacol (1991) 1.14
ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther (2004) 1.10
Metabolism of Zidovudine. Gen Pharmacol (1995) 1.07
Isolation and characterization of an ether glucuronide of zidovudine, a major metabolite in monkeys and humans. Drug Metab Dispos (1990) 1.07
Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms? J Antimicrob Chemother (2009) 1.06
Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol (2009) 1.00
MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Exp Biol Med (Maywood) (2008) 0.99
Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin Infect Dis (1995) 0.99
Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin Ther (1998) 0.99
Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs. J Physiol (2007) 0.96
Drug transporter pharmacogenetics in nucleoside-based therapies. Pharmacogenomics (2010) 0.95
Zidovudine and Lamivudine for HIV Infection. Clin Med Rev Ther (2010) 0.89
The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol (1994) 0.89
Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). Antivir Ther (2004) 0.85
Role of human liver P450s and cytochrome b5 in the reductive metabolism of 3'-azido-3'-deoxythymidine (AZT) to 3'-amino-3'-deoxythymidine. Biochem Pharmacol (1998) 0.84
The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antivir Chem Chemother (2005) 0.83
The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. Br J Pharmacol (2009) 0.79
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell (2012) 12.32
Clinical assessment incorporating a personal genome. Lancet (2010) 10.18
The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science (2008) 8.52
The incidentalome: a threat to genomic medicine. JAMA (2006) 7.24
Genetics. Genomic research and human subject privacy. Science (2004) 6.56
PharmGKB: the Pharmacogenetics Knowledge Base. Nucleic Acids Res (2002) 6.40
A Bayesian framework for combining heterogeneous data sources for gene function prediction (in Saccharomyces cerevisiae). Proc Natl Acad Sci U S A (2003) 6.19
From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med (2011) 4.05
Knowledge acquisition, consistency checking and concurrency control for Gene Ontology (GO). Bioinformatics (2003) 3.97
SAFA: semi-automated footprinting analysis software for high-throughput quantification of nucleic acid footprinting experiments. RNA (2005) 3.95
Associating genes with gene ontology codes using a maximum entropy analysis of biomedical literature. Genome Res (2002) 3.77
Nonparametric methods for identifying differentially expressed genes in microarray data. Bioinformatics (2002) 3.65
Health-information altruists--a potentially critical resource. N Engl J Med (2005) 3.61
The RNA Ontology Consortium: an open invitation to the RNA community. RNA (2006) 3.60
Creating an online dictionary of abbreviations from MEDLINE. J Am Med Inform Assoc (2002) 3.32
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. PLoS Genet (2011) 3.20
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93
Data-driven prediction of drug effects and interactions. Sci Transl Med (2012) 2.93
Challenges in the clinical application of whole-genome sequencing. Lancet (2010) 2.92
Eukaryotic regulatory element conservation analysis and identification using comparative genomics. Genome Res (2004) 2.84
PharmGKB: a logical home for knowledge relating genotype to drug response phenotype. Nat Genet (2007) 2.65
Coarse-grained modeling of large RNA molecules with knowledge-based potentials and structural filters. RNA (2009) 2.63
A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc (2011) 2.53
Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol (2010) 2.52
The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge. Nucleic Acids Res (2007) 2.45
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Bioinformatics challenges for personalized medicine. Bioinformatics (2011) 2.28
Time to organize the bioinformatics resourceome. PLoS Comput Biol (2005) 2.25
MScanner: a classifier for retrieving Medline citations. BMC Bioinformatics (2008) 2.24
Using binning to maintain confidentiality of medical data. Proc AMIA Symp (2002) 2.23
Web-scale pharmacovigilance: listening to signals from the crowd. J Am Med Inform Assoc (2013) 2.19
Using text to build semantic networks for pharmacogenomics. J Biomed Inform (2010) 2.19
Pharmspresso: a text mining tool for extraction of pharmacogenomic concepts and relationships from full text. BMC Bioinformatics (2009) 2.15
Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal (2011) 2.10
PharmGKB: understanding the effects of individual genetic variants. Drug Metab Rev (2008) 2.09
GAPSCORE: finding gene and protein names one word at a time. Bioinformatics (2004) 2.05
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS (2009) 1.95
Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther (2003) 1.94
Computational analysis of Plasmodium falciparum metabolism: organizing genomic information to facilitate drug discovery. Genome Res (2004) 1.92
Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics (2010) 1.91
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol (2002) 1.91
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses (2012) 1.89
Recent progress in automatically extracting information from the pharmacogenomic literature. Pharmacogenomics (2010) 1.88
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
Automating data acquisition into ontologies from pharmacogenetics relational data sources using declarative object definitions and XML. Pac Symp Biocomput (2002) 1.81
PharmGKB: the Pharmacogenomics Knowledge Base. Methods Mol Biol (2013) 1.81
PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. Methods Mol Biol (2005) 1.80
High-throughput single-nucleotide structural mapping by capillary automated footprinting analysis. Nucleic Acids Res (2008) 1.78
Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.78
Using text analysis to identify functionally coherent gene groups. Genome Res (2002) 1.71
Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther (2004) 1.69
The FEATURE framework for protein function annotation: modeling new functions, improving performance, and extending to novel applications. BMC Genomics (2008) 1.64
Challenges for biomedical informatics and pharmacogenomics. Annu Rev Pharmacol Toxicol (2002) 1.61
Finding haplotype tagging SNPs by use of principal components analysis. Am J Hum Genet (2004) 1.61
Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS (2002) 1.58
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol (2014) 1.58
MutDB: annotating human variation with functionally relevant data. Bioinformatics (2003) 1.54
Structural inference of native and partially folded RNA by high-throughput contact mapping. Proc Natl Acad Sci U S A (2008) 1.54
Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics (2011) 1.53
Discovery and explanation of drug-drug interactions via text mining. Pac Symp Biocomput (2012) 1.53
Training the next generation of informaticians: the impact of "BISTI" and bioinformatics--a report from the American College of Medical Informatics. J Am Med Inform Assoc (2004) 1.53
The computational analysis of scientific literature to define and recognize gene expression clusters. Nucleic Acids Res (2003) 1.44
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr (2008) 1.43
Review and management of drug interactions with boceprevir and telaprevir. Hepatology (2012) 1.42
Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships. Hum Mol Genet (2008) 1.42
The functional importance of disease-associated mutation. BMC Bioinformatics (2002) 1.41
Independent component analysis: mining microarray data for fundamental human gene expression modules. J Biomed Inform (2010) 1.39
Local kinetic measures of macromolecular structure reveal partitioning among multiple parallel pathways from the earliest steps in the folding of a large RNA molecule. J Mol Biol (2006) 1.38
Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics (2012) 1.38
A statistical approach to scanning the biomedical literature for pharmacogenetics knowledge. J Am Med Inform Assoc (2004) 1.37
WebFEATURE: An interactive web tool for identifying and visualizing functional sites on macromolecular structures. Nucleic Acids Res (2003) 1.35
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther (2005) 1.35
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr (2006) 1.35
A literature-based method for assessing the functional coherence of a gene group. Bioinformatics (2003) 1.33
A call for the creation of personalized medicine databases. Nat Rev Drug Discov (2006) 1.30
Extracting and characterizing gene-drug relationships from the literature. Pharmacogenetics (2004) 1.30